Recombinant varicella zoster virus glycoprotein e antigen

5 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Recombinant varicella zoster virus glycoprotein e antigen
Treatment and conditionWhere it standsTrials
Recombinant varicella zoster virus glycoprotein e antigen for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for cardiovascular diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for dementiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for herpes zosterPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Recombinant varicella zoster virus glycoprotein e antigen for myocardial infarctionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1